Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

NASDAQ:BBIO opened at $34.90 on Friday. The firm has a market cap of $6.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.07. The company’s 50-day moving average is $32.68 and its ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1 ...

Citi raised the firm’s price target on BridgeBio (BBIO) to $49 from $45 and keeps a Buy rating on the shares following the Q4 report. As of ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$1.31 per share, missing estimates of -$1.15 ...